UK Government Considers Raising NHS Drug Pricing Threshold Amid US Tariff Threats

The UK government is reportedly preparing to increase the pricing threshold used by the National Institute for Health and Care Excellence (NICE) to assess the cost-effectiveness of new medicines. This proposal, which could raise the threshold by 25%, aims to address pressures from the pharmaceutical industry and avoid potential tariffs of up to 100% on imported medicines threatened by US President Donald Trump. Currently, NICE considers drugs costing between £20,000 and £30,000 per quality-adjusted life year (QALY) as providing good value for the NHS.

Change to NHS drug analysis on the table to stave off US tariffs – reportsFiercePharmaGB NewsThe IndependentThe Guardian

The NICE threshold has remained unchanged since 1999, leading to criticism from the pharmaceutical sector, which argues that the current framework undervalues innovative treatments. The Association of the British Pharmaceutical Industry (ABPI) has called for an increase to between £40,000 and £50,000 per QALY to align with inflation and modern drug development costs. The stagnation of this threshold has been cited as a factor in major pharmaceutical companies, including Merck & Co. and AstraZeneca, pausing or canceling investments in the UK.

FiercePharma

Raising the NICE threshold could facilitate access to more expensive, potentially life-extending treatments for NHS patients. Claire Rowney, chief executive of Breast Cancer Now, described the change as a "game-changer." However, experts warn that this could significantly increase the NHS's overall drug expenditure, potentially straining its budget. Azeem Majeed, a professor at Imperial College London, noted that while access to innovative treatments may improve, it would also place additional pressure on the NHS's financial resources.

Change to NHS drug analysis on the table to stave off US tariffs – reports

Critics, including the Nuffield Trust, argue that increasing the threshold could lead to higher costs for the NHS without corresponding health benefits for the population. Sally Gainsbury, a senior policy analyst at the Nuffield Trust, emphasized that the current NICE threshold is already too high and that additional spending on new drugs could detract from funding for essential services like GP access and emergency care. Dr. Dan Howdon from the University of Leeds echoed this sentiment, stating that any increase in the threshold would be driven by pressures from the pharmaceutical industry rather than evidence-based healthcare needs.

The Independent

The UK government has confirmed that it is in "advanced discussions" with the US administration to secure a favorable outcome regarding drug pricing. A government spokesperson highlighted the importance of the pharmaceutical sector to the NHS and the economy, stating, "Through our Life Sciences Sector Plan, we’ve committed to working with industry to accelerate growth in spending on innovative medicines." Meanwhile, the Liberal Democrats have criticized the government's approach, questioning the financial implications of the proposed changes and the potential impact on other NHS services.

GB NewsChange to NHS drug analysis on the table to stave off US tariffs – reportsThe GuardianThe IndependentFiercePharma

While the government is moving towards increasing the NICE threshold, there is significant debate regarding the potential financial impact on the NHS. Some experts argue that the current pricing framework is already too lenient, while others contend that raising the threshold is essential for attracting pharmaceutical investments. The lack of consensus on the appropriate threshold reflects broader tensions between healthcare funding and pharmaceutical industry interests.

FiercePharma

• “ Claire Rowney, chief executive at Breast Cancer Now, added: “If, as reports suggest, the Government were to significantly increase the cost-effectiveness threshold for medicines, this could be a game-changer that sees more people getting access to vital life-extending treatments.” — Claire Rowney, Chief Executive, Breast Cancer Now

Change to NHS drug analysis on the table to stave off US tariffs – reports

• “ A Nice spokesperson said: “In a health system such as ours funded by general taxation, it is for the Government to decide how much to spend on health in the context of other spending priorities within the health system and beyond.” — NICE Spokesperson

Change to NHS drug analysis on the table to stave off US tariffs – reports

• “Even if the NHS budget is topped up to fund a higher spend on new drugs, an increase in the Nice threshold will mean a larger share of the NHS’s total funding will be diverted to new drugs that bring a lower level of health benefit to the population as a whole than had the extra funding been spent on extending or shoring up existing services and treatments, such as GP appointments and elective surgery,” — Sally Gainsbury, Senior Policy Analyst, Nuffield Trust

The Independent

• “I am not aware of any research, taking improving the health of the nation as the goal of healthcare spending, that suggests it is too low. Any move to increase the threshold would be motivated by twin pressures that are geopolitical and from the pharmaceutical industry.” — Dr. Dan Howdon, Associate Professor, University of Leeds

Change to NHS drug analysis on the table to stave off US tariffs – reports